(CUTR) Cutera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2321091082

CUTR: Vascular Treatments, Skin Resurfacing, Hair Removal, Fat Reduction, Acne Treatment

Cutera, Inc. (NASDAQ:CUTR) is a global leader in aesthetic and dermatological solutions, offering a comprehensive suite of energy-based devices and skincare products for medical professionals. The company specializes in developing and marketing advanced technologies that address a wide range of aesthetic concerns, including acne, skin resurfacing, body contouring, hair removal, and tattoo removal. Its product portfolio includes AviClear, a groundbreaking laser treatment for inflammatory acne; Secret PRO, a dual-action device combining fractional CO2 and RF microneedling for skin revitalization; and truFlex, a bio-electrical stimulation system designed for muscle toning and contouring. Additionally, the company offers truSculpt, a high-powered RF system for non-invasive fat reduction and skin tightening, as well as Enlighten SR/III, a dual-wavelength laser platform for tattoo removal and pigmented lesion treatment. Cutera also provides Excel HR for permanent hair reduction and xeo, a multi-application platform for hair removal, vascular lesion treatment, and skin rejuvenation. Its products are distributed through a combination of direct sales, international distributors, and service networks.

On March 5, 2025, Cutera, Inc. filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas, signaling significant financial restructuring efforts. The company, founded in 1998 and headquartered in Brisbane, California, has faced challenges in maintaining profitability despite its innovative product offerings. Its financial struggles are reflected in its current market capitalization of $1.99M and a price-to-sales ratio of 0.01, indicating poor revenue generation relative to its market value. The companys stock price has declined sharply, trading at $0.11 as of the latest data, with key moving averages (SMA20: 0.34, SMA50: 0.40, SMA200: 0.82) all above the current price, suggesting bearish momentum. The average true range (ATR) of 0.06 highlights moderate volatility in recent trading sessions.

Based on the provided technical and fundamental data, Cutera, Inc. (NASDAQ:CUTR) is expected to face continued downward pressure over the next three months. The stock price, currently trading at $0.11, is likely to test lower support levels due to the bearish crossover of its short- and long-term moving averages (SMA20: 0.34, SMA50: 0.40, SMA200: 0.82). The companys poor fundamental health, including a market cap of $1.99M and a P/S ratio of 0.01, further exacerbates the negative outlook. The high price-to-book ratio (P/B: 61.48) and the absence of a forward P/E ratio underscore the significant financial distress and limited investor confidence. Additionally, the recent Chapter 11 filing suggests ongoing operational and liquidity challenges, which may further weigh on the stock price. Technically, the ATR of 0.06 indicates moderate volatility, but the overall trend remains bearish.

Additional Sources for CUTR Stock

CUTR Stock Overview

Market Cap in USD 2m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2004-03-31

CUTR Stock Ratings

Growth 5y -85.5%
Fundamental -57.0%
Dividend 0.0%
Rel. Strength Industry -95.1
Analysts 3.67/5
Fair Price Momentum 0.07 USD
Fair Price DCF -

CUTR Dividends

No Dividends Paid

CUTR Growth Ratios

Growth Correlation 3m -1.4%
Growth Correlation 12m -91.6%
Growth Correlation 5y -56.1%
CAGR 5y -62.62%
CAGR/Max DD 5y -0.63
Sharpe Ratio 12m -1.16
Alpha -106.86
Beta 1.85
Volatility 268.39%
Current Volume 29608.6k
Average Volume 20d 221.8k
What is the price of CUTR stocks?
As of March 14, 2025, the stock is trading at USD 0.10 with a total of 29,608,605 shares traded.
Over the past week, the price has changed by -17.04%, over one month by -76.85%, over three months by -73.02% and over the past year by -95.11%.
Is Cutera a good stock to buy?
No, based on ValueRay Fundamental Analyses, Cutera (NASDAQ:CUTR) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -56.96 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CUTR as of March 2025 is 0.07. This means that CUTR is currently overvalued and has a potential downside of -30%.
Is CUTR a buy, sell or hold?
Cutera has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold CUTR.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CUTR stock price target?
According to ValueRays Forecast Model, CUTR Cutera will be worth about 0.1 in March 2026. The stock is currently trading at 0.10. This means that the stock has a potential downside of -20%.
Issuer Forecast Upside
Wallstreet Target Price 2 1900%
Analysts Target Price 2 1900%
ValueRay Target Price 0.1 -20%